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Abstract
Human norovirus (NoV) is now recognized as one of the most important causative agents of gastroenteritis in all age groups worldwide.
During the course of NoV infection, symptoms are usually mild and disappear within 48 h after onset. The incidence of NoV infection is
high, with hundreds of cases per 10 000 of the population, although the number of infections is still underestimated. Epidemiological surveys
conducted in Europe and North America have shown that NoV infections constitute a major disease burden, especially for young children
and the elderly, in whom NoV infection leads to high rates of hospitalization and mortality. NoV infections are also of concern in hospitals,
where viral infections can be persistent in immunocompromised patients. Although the cost of NoV infection in the hospital community has
not yet been clearly established, it appears that NoV infections could cost hundreds of thousands of euros in terms of unit closure, and
NoV-related sickness in patients and health workers. Besides their clinical burden, NoVs, as foodborne pathogens, also cause to millions of
dollars of losses for the healthcare system and the food industry. Recent estimates in the USA showed that, annually, NoV illness cost
$2 billion and led to a loss of approximately 5000 quality-adjusted life-years, making NoV one of the top ﬁve pathogens causing enteric
illnesses. The highest cost among 14 foodborne pathogens is also attributed to human NoV in The Netherlands. This accumulation of
evidence underlines the enormous impact of NoV on populations.
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In the past, studies on norovirus (NoV) were limited by the
lack of sensitive detection tools. The development of molec-
ular methods has markedly improved NoV detection [1]. Over
the last decade, laboratory networks were set up throughout
the world, and have led to a better understanding of the role
of NoV as a cause of acute gastroenteritis (AGE). The
increasing use of real-time RT-PCR for diagnostic purposes has
improved both the sensitivity and speciﬁcity of NoV detection.
Fast and accurate detection methods enable the follow-up of
NoV infection and estimation of the viral load in patients.
These new molecular tools have greatly improved the value of
epidemiological studies. Population-based studies are now
feasible, and have greatly improved the precision of estimates
of the NoV health and economic burden.
Symptoms
The time between exposure and the onset of gastroenteritis
symptoms (i.e. the incubation period) for NoV is brief, being
estimated as 1.2 days on average [2]. Diarrhoea is the
predominant symptom, being present in c. 90% of cases, with
vomiting being present in c. 75% of cases [3]. The onset can
occur with no prodrome, sometimes resulting in public
vomiting incidents, which may be a particularly effective
mechanism of transmission [4,5]. Vomiting may also occur in
the absence of diarrhoea. Other symptoms may include
abdominal cramps, fever, headache, chills, and myalgia. Symp-
toms generally persist for 2–3 days, but may last longer in
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young children and the elderly infected in outbreaks in
healthcare facilities [3,6]. The shedding of virus in stools
begins before the onset of symptoms, typically peaks (at c. 1010
viral particles per gram of stool) on day 4 following exposure,
and may persist for many weeks in the general population, or
for months in immunocompromised individuals [3,7,8]. There
are few quantitative data regarding severity (i.e. number of
episodes of diarrhoea and vomiting, and dehydration) in adults,
but, in children, NoV gastroenteritis tends to be less severe
than rotavirus gastroenteritis [9–11].
Incidence of the Disease
Although NoVs are well recognized as constituting the most
common cause of outbreaks of AGE, data concerning the
incidence and disease burden of sporadic illness in the wider
community are sparse, for a number of reasons. NoV AGE is
usually mild and lasts for <72 h, so relatively few individuals
seek medical care and, for those who do, specimens are
frequently not taken or tested for NoV. The lack of a highly
sensitive and speciﬁc diagnostic test presents challenges on a
number of levels. Medical records (such as hospital discharge
datasets) rarely include speciﬁc codes for NoV (ICD9 008.63
and ICD10 A08.11), owing to the absence of a conﬁrmed
diagnosis. Also, and more fundamentally, NoV is also fre-
quently detected in stools of healthy individuals, which
complicates the interpretation of individual test results. For
these reasons, estimates of disease incidence and burden are
compiled from a number of sources and with various
methodological approaches.
Indeed, we are aware of only two countries, The Nether-
lands and the UK, where population-based cohorts have been
followed with gastroenteritis cases being systematically tested
for NoV in stools, and where the data obtained have been
subsequently used to generate disease incidence estimates.
These studies have generated fairly consistent estimates of
NoV disease incidence of 380 per 10 000 population
(95% CI 264–544) for The Netherlands [12,13] and 450 per
10 000 population (95% CI 380–520) and 470 per 10 000
population (95% CI 391–565) for the UK [14,15]. Other
studies that either attributed a fraction of all AGE cases to
NoV, or extrapolated data based on healthcare-seeking
cases, have led to somewhat higher estimates, ranging from
650 to 1040 per 10 000 population for the USA [16,17] and
Canada [18].
Estimates of outpatient incidence (i.e. cases presenting to
a general practitioner) range internationally from 21 to 92 per
10 000 population [13–16,19,20], suggesting that approxi-
mately one in 10 community cases seek care. Hospitalization
rates are an order of magnitude lower, and range from 1.2
to 2.4 per 10 000 population (the USA, the UK, and The
Netherlands) [13,17,21,22]. NoV-associated deaths are rare,
with an incidence of 0.19–0.40 deaths per 10 000 population
(the USA and The Netherlands) [13,23].
Notably, none of these disease incidence estimates are for
populations in developing countries, where the disease burden
is probably greater, for a number of reasons, potentially
including poorer water, sanitation and hygiene conditions, and
a weaker immune response to infection. Globally, diarrhoeal
disease is estimated to result in 1.45 million deaths and
89.5 million disability-adjusted life-years lost annually [24,25].
In a large systematic literature review of 137 studies, NoV was
estimated to be associated with 18% (95% CI 17–20%) of
gastroenteritis cases globally [26]. The ﬁgure is surprisingly
lower, at 12% (95% CI 9–15%), in high-mortality developing
countries. This discrepancy is probably attributable to a
greater burden of other bacterial and parasitic causes of
disease in such countries, rather than a lower disease burden
in these settings.
Young children
Young children (aged <5 years) have the highest incidence of
NoV AGE. The disease incidence in this age group is estimated
to be 21 400 (15 900–27 700) per 100 000 population, which
is approximately 6.5 times the incidence for the population
aged ≥5 years [15]. Rates of NoV-associated outpatient visits,
emergency department visits and hospitalizations are also
highest for this age group. In the USA, where rotavirus
vaccines are in widespread use, NoV is now the leading cause
of medically attended AGE for children aged <5 years [27].
Again, data from developing countries are lacking. Although
NoV is associated with 18% (95% CI 15–21%) of diarrhoeal
disease globally in children aged <5 years [26], NoV is also
frequently detected in stools of diarrhoea-free children,
making it difﬁcult to deﬁnitely attribute a proportion of the
diarrhoeal disease burden to NoV for children in low-income
settings [28,29]. Deﬁning the disease burden for children in
low-income countries with the most robust methodology is an
important area of future research.
The elderly
The elderly (usually deﬁned as being aged ≥65 years) suffer
disproportionately from severe outcomes of NoV infection. In
the USA, 90% of the c. 800 deaths/year occur among the
elderly [23]. The estimated case-fatality ratio in this age group
(estimated at approximately six per 10 000 cases) is approx-
imately 20 times that in the population aged 18–64 years
[13,30]. Although the elderly in the community do not appear
to have an overall higher risk for infection, those living in
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healthcare facilities may have a greater risk of being affected
during outbreaks [31,32]. These outbreaks are disproportion-
ately caused by genogroup II.4 viruses, which, independently of
other factors, appear to result in more severe disease
outcomes, including hospitalizations and deaths [30]. There
is mounting evidence that NoV is a cause of excess mortality
during outbreaks in nursing homes [33].
NoV infections in the context of other severe pathologies
In immunocompetent individuals, NoV gastroenteritis is gen-
erally self-limiting and of short duration, although asymptom-
atic excretion of the virus in faeces has been observed to
last for up to 3 weeks in adults [3] or even for more than
47 days in young children [34] and for up to 32 days in elderly
patients [35]. However, in immunocompromised patients,
including those with congenital conditions and acquired
immunodeﬁciencies, NoV can cause severe diarrhoea, often
with prolonged symptoms and excretion.
Numerous studies have reported the excretion of NoV for
months and persistent diarrhoea in patients during iatrogenic
immunosuppression following transplantation of various
organs, including the intestine, kidney, liver, pancreas, and
heart [36–38], as well as in patients who have undergone
allogeneic haematopoietic stem cell transplantation [39–42].
Chronic diarrhoea lasting for >2 years has been described in a
heart transplant patient [36]. Patients suffering from immuno-
suppressive disease or with oncological disorders can also be
subject to persistent NoV infection. Capizzi et al. reported
two patients suffering from chronic lymphocytic leukaemia
[43] who developed chronic diarrhoea, lasting for up to a year,
caused by NoV. A previous study also described paediatric
oncology patients who suffered from prolonged gastroenteritis
and shedding of NoV for up to 420 days [44]. One human
immunodeﬁciency virus-positive patient with chronic NoV
infection and persistent diarrhoea has been reported [45].
Prolonged NoV shedding has also been observed in patients
with inherited immune deﬁciencies. Chronic NoV shedding for
>1 year has been described in a 2-month-old child with severe
combined immunodeﬁciency syndrome [46]. More recently,
Frange et al. reported the detection of NoV in children
suffering from different types of genetic immunodeﬁciency
with prolonged shedding for >9 months [47].
Apart from being a signiﬁcant cause of prolonged morbidity,
chronic NoV infection in high-risk patients may lead to severe
outcomes, necessitating extended hospitalization, with a
median of 73 days, as reported in one study [41]. Severe
weight loss requiring enteral or parenteral nutrition, malnu-
trition and severe dehydration, growth retardation and even
death have been observed in immunocompromised hosts as a
consequence of NoV infection [41–44,48]. Mattner et al.
reported cardiac complications in a patient with cardiovascular
disease after NoV infection [49]. Furthermore, in transplant
recipients, who commonly develop gastroenteritis as a result
of conditioning therapy, graft-versus-host disease, or drugs, it
is crucial to distinguish these clinical complications from NoV
diarrhoea, to avoid inappropriate and harmful treatment.
Economic Impact of NoV
As a result of the health burden of NoV, there is a
considerable ﬁnancial impact. Among public health ofﬁcials,
cost of illness and health-adjusted life-years are increasingly
popular tools with which to evaluate the burden of an illness,
despite the fact that there is some uncertainty in determining
the real impact of infectious pathogens, given the inﬂuence of
comorbidity (chronic NoV infection in transplantees), genetic
resistance of the population (e.g. non-secretor status and fast
IgA responders), or awareness of the population regarding
NoV infection [50]. Although estimating the burden of NoV is
still very challenging, over the past few years the ﬁnancial
impact of NoV as a foodborne and nosocomial pathogen has
been increasingly studied.
NoV and foodborne diseases
Soon after its discovery, human NoV was implicated as a
causative agent in foodborne and waterborne outbreaks of
gastroenteritis [51]. To date, there have been numerous
reports of NoV outbreaks in the literature, linked to
waterborne and foodborne transmission [52]. In Europe,
10% of reported NoV outbreaks are reported by investigators
to be spread primarily by foodborne transmission, as com-
pared with 26% in the USA [53,54]. However, if mode of
transmission is assigned to the outbreak on the basis of
genotype proﬁles and other outbreak characteristics, the
foodborne percentage rises to 20% [55]. These and similar
surveillance data have helped researchers to generate better
estimates of the foodborne disease burden. In 1999, one of the
ﬁrst large-scale estimates regarding foodborne pathogens
showed, surprisingly, that, every year, NoV was responsible
for 23 million cases of gastroenteritis, 9.2 million of which
were food-related, representing 66.6% of all foodborne
illnesses, 20 000 hospitalizations and 124 food-related deaths
[56]. Despite the fact that only 18–41% of reported foodborne
cases have a known aetiology, and the estimate is based on
extrapolations of data, human NoV is one of the main
causative agents of foodborne illnesses in the USA, being
responsible for c. 60% of all cases [17]. In contrast, studies
in the UK and The Netherlands showed that NoV was
responsible for only 3.6% and 15.6% of foodborne illnesses,
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respectively [57,58]. The numbers of hospitalizations and
deaths resulting from foodborne disease were usually very
high in reports from the USA, with NoV being associated with
15–20% of hospitalizations and 2–10% of deaths. In the UK and
Australia, NoV was responsible for <1.5% of the hospitaliza-
tions and deaths [57,59]. In the USA, NoV is estimated to
cause the majority of mild and moderate cases of foodborne
illness, bacterial pathogens being responsible for most of the
hospitalizations and deaths. However, NoV still ranks second
and fourth in these categories, respectively [60]. These
foodborne illnesses are estimated to result in direct and
indirect costs of $2 billion, and result in a loss of 5000
quality-adjusted life-years every year [60]. The most recent
analogous ﬁgures for The Netherlands indicate that NoV
infections cost up to $130 million each year, representing the
highest cost of illness among food-related pathogens,
$22.1 million of which could be directly attributed to
contaminated food, corresponding to $1.31 per inhabitant
[61]. An older study in the same country estimated that the
mean cost was c. $90 per case for the year 1999 [62]. In New
Zealand, a cost of $3 million, representing $0.67 per inhab-
itant, could be directly attributed to NoV in foodborne
diseases. Food-related NoV infection accounted for approx-
imately 4.66 and 8.63 disability-adjusted life-years per 100 000
inhabitants in New Zealand and The Netherlands, respectively,
with a higher proportion of years being lost because of
premature deaths in the Dutch study [58,63].
NoV in medical institutions
NoV infection is increasingly being recognized as a major
threat for the hospital community. NoV infections affect both
patients and healthcare workers. The direct cost for the
healthcare system is far greater than the indirect non-health-
care costs, which include absenteeism and loss of productivity.
There are reports of a large number of hospitalizations
following NoV infection. Between 2002 and 2008, 710 725
cases of NoV gastroenteritis were reported in Germany, 26%
of which led to hospitalization. In the same study, the authors
observed that 49% of the NoV-related hospitalizations were
nosocomially acquired, mainly in elderly patients [64]. Esti-
mates in England showed that NoV was responsible for 8.7% of
gastroenteritis-related hospitalizations, increasing to 19%
among the elderly; these admission also pose a risk of
nosocomial infection [22]. A survey conducted in England in
1999 estimated that nosocomial gastroenteritis outbreaks
resulted in an annual loss to the National Health Service of
$184 million, a large part of which was attributable to NoV
infection [65]. The elderly are most at risk, and it has been
estimated that NoV is responsible for one excess hospitaliza-
tion and one death every four and nine outbreaks, respectively,
in nursing homes [33]. Models have suggested that deaths
associated with NoV infection might reach 20% among people
aged ≥65 years in England and Wales [66]. In the USA, it has
been estimated that NoV infection might be responsible for
71 000 hospital admissions per year, representing an average
cost of $493 million each year [21]. For young children in the
USA in 2009 and 2010, it was estimated that NoV was
responsible for 14 000 hospitalizations, 281 000 emergency
visits, and 627 000 outpatient visits, representing $273 million
of direct health costs for each of the 2 years, nationwide, for
children aged <5 years [27].
Analysis of data from the literature showed that NoV was
the most common pathogen leading to ward closure (in 44% of
194 outbreaks) [67]. NoV infection can lead to costly ward
closure, as exempliﬁed by a nosocomial NoV outbreak that
occurred in a tertiary hospital in the USA. The outbreak
affected 90 patients and 265 healthcare workers; it required
the closure of several units and thorough disinfection of the
facilities. Additionally, the authors observed a set-back in the
treatment programme and a decrease in medical activities
while new admissions were stopped and absentees from the
staff were replaced, resulting in a total cost of $657 644 [68].
More recently, the follow-up of 16 patients suffering from NoV
infection in an internal medicine unit in a tertiary hospital
showed that NoV infection led to an additional cost of
$40 675: $37 968 of revenue loss for bed closure, and $2707
for additional laboratory analyses. Differences in NoV-related
hospitalization costs might be explained by several factors,
such as the number of people affected (patients and healthcare
workers), the duration of the outbreak, and the types and
volume of medical activity that have been directly affected by
the occurrence of NoV infection.
Conclusion
NoV has a major clinical and ﬁnancial impact on the
populations of industrialized countries. All age groups are
affected by NoV, but young children and the elderly are
subject to higher incidence rates and more severe outcomes
of the disease. The symptoms associated with NoV infection
are somewhat similar to those observed for rotavirus
infection in otherwise healthy patients. However, NoVs are
increasingly being found in immunocompromised patients,
such as transplantees, in whom chronic infection is a
frequently reported problem. In the elderly, complications
resulting from dehydration and a weak immune system also
provide a favourable situation for NoV infection. Besides the
clinical aspects of NoV infection, there is also a considerable
ﬁnancial impact. Large-scale studies have all shown that NoV
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infection is responsible for the majority of mild and
moderate cases of gastroenteritis in the community. How-
ever, studies have shown that nosocomial NoV infections
can also be costly for the hospital community. For
foodborne diseases, the latest estimate showed that approx-
imately half of all cases of AGE were NoV-related, and that
these represented a loss of several million dollars in terms
of direct and indirect health costs. Although NoV is a major
cause of foodborne disease, most NoV infections result
from person-to-person transmission, and the NoV burden
might be far greater than estimated. For the food industry,
the mandatory decontamination of the production line after
accidental NoV contamination could lead to substantial
additional costs. NoV is thus a major health issue for the
food industry, but can be dealt with by implementing good
standards and practices [69].
Early detection and the containment of outbreaks in
hospitals, the education of professionals through the estab-
lishment of virus-speciﬁc hazard analysis and critical control
points procedures in the food and catering industries and
the protection of vulnerable populations with affordable
vaccines are avenues that can be explored to reduce the
burden of NoV [70–73].
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